News | May 18, 2021
Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The commercial production in the SML was started in November 1989.
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Subscribe To Our Newsletter & Stay Updated
